Sexual Health & Libido
Research compounds studied for central arousal pathways, hormonal axis restoration, and sexual response enhancement. Includes FDA-approved compounds and hormonal modulators.
Most researched for Sexual Health & Libido
PT-141
The only compound in this category with FDA approval for a sexual health indication (female hypoactive sexual desire disorder under the name Vyleesi). PT-141 activates melanocortin receptors in the brain to increase sexual desire centrally - a distinct mechanism from PDE5 inhibitors (Viagra/Cialis) which work peripherally. On-demand dosing, fast onset, validated across genders in clinical research.
Oxytocin
aka Pitocin, Syntocinon
Oxytocin is a natural nine amino acid hormone produced in the hypothalamus and released from the posterior pituitary. Acting on oxytocin receptors, it stimulates uterine contractions and milk ejection. The synthetic form is FDA approved as Pitocin to induce or augment labor and to control postpartum bleeding. Intranasal oxytocin is separately studied for social bonding, autism, and anxiety, though those uses are not approved.
How it works: It activates oxytocin receptors, driving uterine smooth muscle contraction and milk ejection and modulating social behavior.
Labor induction; postpartum hemorrhage; social bonding; autism research
Research dose
20-40 IU, As needed; intranasal or SubQ
Real-world (reported)
20–40 IU intranasal spray 20–30 min before social/sexual activity. Start at 20 IU.
Administration
Intranasal (most practical); SubQ (research); IV (medical obstetrics only)
Timing
20–45 min before desired effect
Cycle length
As needed (not cycled)
Real-world figures are community-reported, not medical advice.
Common side effects: Nausea; vomiting; uterine hyperstimulation; injection site reactions; abdominal pain
Community take: [ANECDOTAL] Popular for intimacy/social contexts. 'Love hormone' effect widely reported. Some use PT-141 + oxytocin combo. Variable response — highly individual.
- Onset
- Social/emotional effects within 30–45 min; sexual effects within 20–30 min
- Half-life
- Approximately 3 minutes
- Storage
- Dry: Nasal spray: refrigerate; follow mfr guidelines · Reconstituted: SubQ reconstituted: refrigerate; use within 21 days
- Reconstitution
- Nasal spray: pre-filled or custom pharmacy. SubQ: add BAC water.
- Rare side effects
- Uterine hyperstimulation (DANGEROUS in pregnancy — can cause fetal distress/death); water intoxication (rare at high doses); excessive trust/social manipulation vulnerability
- Contraindications
- PREGNANCY (can induce labor/fetal distress — CONTRAINDICATED); cardiovascular disease; history of hyponatremia; Significant cephalopelvic disproportion; Unfavorable fetal positions (transverse lie); Cord presentation or prolapse; Placenta previa or vasa previa
- Drug interactions
- Antihypertensives; SSRIs (complex serotonin/oxytocin interaction); vasoconstrictors
- Recommended bloodwork
- Sodium levels (hyponatremia risk at high doses); BP
- Stacks well with
- PT-141: reported additive sexual effects [ANECDOTAL]. Avoid combining with other vasodilators.
- Secondary uses
- Anti-anxiety; empathy; prosocial behavior; post-workout recovery; lactation (endogenous role)
- Legal status
- Approved
- Typical price
- $20–$50 / research nasal spray
- Research evidence
- Approved - large human trials
- Indications
- Labor induction and augmentation; Postpartum hemorrhage prevention and treatment; Social cognition and autism spectrum disorder research; Anxiety and stress-related disorder studies; PTSD treatment augmentation research; Pair bonding and trust research
- Chemical data
- CAS 50-56-6 · C43H66N12O12S2 · 1007.19 Da
- Amino acids
- 83 aa
Key risk: Excessive or improper administration can cause uterine rupture, water intoxication with seizures, and maternal or fetal death.
Nafarelin
aka Synarel, Nafarelin acetate
Nafarelin is a synthetic agonist analog of gonadotropin-releasing hormone delivered as a nasal spray. It is FDA approved for the management of endometriosis and for central precocious puberty in children. Continuous administration desensitizes the pituitary, suppressing gonadotropin and sex steroid production after an initial stimulatory phase.
How it works: It is a potent GnRH receptor agonist that after initial stimulation downregulates pituitary receptors, suppressing sex steroid production.
Endometriosis; central precocious puberty; reproductive hormone suppression
Research dose
200-400 mcg, Twice daily intranasal (Synarel label)
Real-world (reported)
Primarily Rx-driven.
Administration
Intranasal
Timing
Twice daily (AM + PM)
Cycle length
6 months max per FDA label
Real-world figures are community-reported, not medical advice.
Common side effects: Hot flashes; headache; nasal irritation; decreased libido; vaginal dryness
Community take: [ANECDOTAL] Primarily Rx medical. Limited gray-market interest in menstrual cycle and IVF protocols.
- Onset
- Hormonal suppression 2–4 wks
- Half-life
- 2 to 3 hours
- Storage
- Dry: Refrigerate 2–8°C; do not freeze · Reconstituted: Refrigerate; follow label
- Reconstitution
- N/A (pre-formulated nasal spray)
- Rare side effects
- Bone density loss (>6 mo — limit treatment); depression; menopausal symptoms; testosterone suppression (males)
- Contraindications
- Pregnancy; hormone-sensitive cancers (flare before suppression); osteoporosis
- Drug interactions
- Estrogen/testosterone (antagonistic); bone loss meds
- Recommended bloodwork
- Bone density (DEXA if >6 mo); LH; FSH; estradiol/testosterone; CBC
- Stacks well with
- Add-back therapy required for >6 mo endometriosis (FDA label — estrogen/progesterone).
- Secondary uses
- IVF down-regulation; hormone-sensitive cancer (research)
- Legal status
- US: FDA-approved (Synarel) · UK: Prescription-only · Canada: Prescription-only · Australia: TGA-approved (Rx) · EU: EMA-approved (Rx)
- Typical price
- Brand ~$200–$400/month
- Research evidence
- Approved - large human trials
- Chemical data
- CAS 76932-56-4 · C66H83N17O13 · 1322.5
Key risk: Loss of bone mineral density with prolonged use as a result of induced low estrogen levels.
HCG
aka Human Chorionic Gonadotropin, Pregnyl, Ovidrel
Human chorionic gonadotropin is a glycoprotein hormone that mimics luteinizing hormone. FDA approved uses include inducing ovulation in selected infertile women after menotropin pretreatment, treating hypogonadotropic hypogonadism in males, and treating prepubertal cryptorchidism not caused by anatomical obstruction. It stimulates gonadal steroid production.
How it works: It acts on luteinizing hormone receptors in the gonads, triggering ovulation in females and testosterone production in males.
Ovulation induction; male hypogonadotropic hypogonadism; prepubertal cryptorchidism
Administration
SC
Timing
No specific time of day; maintain consistent schedule✓ Rotate injection sites
Cycle length
Ongoing while on TRT; or 6-12 weeks for PCT/fertility protocols
Common side effects: Injection site pain; headache; irritability; edema; fatigue
- Half-life
- 23 to 37 hours
- Reconstitution
- Bacteriostatic water
- Contraindications
- Pregnancy (risk of virilization/teratogenicity); Androgen-dependent or estrogen-dependent tumors (prostate cancer, breast cancer); Undiagnosed ovarian enlargement or ovarian cysts; Precocious puberty
- Legal status
- Approved
- Research evidence
- Approved - large human trials
- Indications
- Male hypogonadism treatment; Ovulation induction in fertility treatments; Cryptorchidism treatment in pediatric patients; Testosterone restoration adjunct therapy
- Chemical data
- CAS 9002-61-3 · Glycoprotein heterodimer (~25.7 kDa peptide + ~10-15 kDa glycans) · 36700 Da
- Amino acids
- 156 aa
Key risk: Ovarian hyperstimulation syndrome when used for ovulation induction, which can become severe and life threatening.
Triptorelin
aka Trelstar, Decapeptyl, Triptodur
Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone. It is FDA approved for the palliative treatment of advanced prostate cancer and for central precocious puberty in children, and it is also used in endometriosis and assisted reproduction. Continuous receptor stimulation ultimately suppresses testosterone and estrogen production after an initial surge.
How it works: Continuous stimulation of pituitary GnRH receptors first raises then downregulates them, suppressing sex hormone production.
Advanced prostate cancer; central precocious puberty; endometriosis; assisted reproduction
Research dose
100-500 mcg, PCT: SINGLE DOSE only (one injection); medical: depot injection q1–3 months
Real-world (reported)
100 mcg SubQ single dose. Wait 2–3 days then begin SERM if needed. Very advanced use — proceed only with bloodwork.
Administration
SubQ / IM / SC depot
Timing
PCT: single injection timing varies by protocol
Cycle length
PCT: single dose, then wait for HPG restart; medical: chronic
Real-world figures are community-reported, not medical advice.
Common side effects: Hot flashes; loss of libido; erectile dysfunction; injection site reactions; fatigue
Community take: [ANECDOTAL – bodybuilding community] 'Nuclear option' for PCT restart. Single 100 mcg dose used by some after heavy AAS cycles. Works when SERMs fail. Community experience limited vs conventional PCT.
- Onset
- LH surge within 4–8h of PCT dose; testosterone rise 1–2 wks
- Half-life
- 2 to 3 hours
- Storage
- Dry: Fridge 2–8°C; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 0.1 mg vial = 0.1 mg/mL
- Rare side effects
- Testosterone crash with repeated dosing (suppression); reduced bone density long-term (medical use); anaphylaxis (rare)
- Contraindications
- Prostate cancer (stimulates before suppressing — tumor flare); pregnancy; ongoing steroid use; Known hypersensitivity to triptorelin; GnRH; or any GnRH agonist; Pregnancy (Category X - may cause fetal harm); Breastfeeding; Undiagnosed abnormal vaginal bleedingFrequency distribution of reported side eff
- Drug interactions
- Sex hormones; antiandrogens; drugs affecting QT interval
- Recommended bloodwork
- LH; FSH; testosterone; estradiol; SHBG — timing-specific post-PCT
- Stacks well with
- SERMs (Clomid, Nolvadex): sometimes used after triptorelin PCT to maintain restart.
- Secondary uses
- Prostate cancer treatment (FDA-approved); endometriosis; gender-affirming care
- Legal status
- Approved
- Typical price
- $30–$80 / 0.1 mg vial
- Research evidence
- Approved - large human trials
- Indications
- Advanced prostate cancer treatment (androgen deprivation therapy); Endometriosis management; Central precocious puberty treatment; Uterine fibroid symptom management
- Chemical data
- CAS 57773-63-4 · C64H82N18O13 · (Da
- Amino acids
- 246 aa
Key risk: Transient tumor flare from an initial surge in testosterone, which can worsen prostate cancer and cause spinal cord compression or urinary obstruction.
HMG
aka Menotropins, Human Menopausal Gonadotropin, Menopur
Human menopausal gonadotropin, also called menotropins, is a purified preparation providing follicle-stimulating and luteinizing hormone activity extracted from the urine of postmenopausal women. It is FDA approved to promote development of multiple ovarian follicles in women without primary ovarian failure who are undergoing assisted reproductive technology. It supports follicular growth and maturation.
How it works: It supplies follicle-stimulating and luteinizing hormone activity that stimulates ovarian follicle recruitment, growth, and maturation.
Assisted reproduction; multiple follicular development; ovulation induction
Administration
SC
Timing
No specific time of day; consistency is key✓ Rotate injection sites
Cycle length
7-20 days per cycle (women, monitored); 3-6 months (men, spermatogenesis)
Common side effects: Injection site reactions; abdominal pain; headache; nausea; ovarian enlargement
- Half-life
- 11 to 13 hours
- Contraindications
- Primary ovarian failure; Uncontrolled thyroid or adrenal insufficiency; Sex hormone-dependent tumors; Unexplained uterine bleeding
- Legal status
- Approved
- Research evidence
- Approved - large human trials
- Indications
- Controlled ovarian hyperstimulation for IVF; Ovulation induction in anovulatory women; Male hypogonadotropic hypogonadism treatment; Fertility research and reproductive endocrinology
- Chemical data
- CAS 9002-68-0 · Glycoprotein mixture (FSH ~35.5 kDa + LH ~28.5 kDa) · 35000 Da
- Amino acids
- 106 aa
Key risk: Ovarian hyperstimulation syndrome, which can be severe and life threatening, along with an increased risk of multiple gestation.
Gonadorelin
aka GnRH, LHRH, Factrel
Gonadorelin is a synthetic form of gonadotropin-releasing hormone that is identical to the natural hormone. When delivered in pulses it stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone. Sold under the brand Factrel, it is FDA approved as a diagnostic agent for evaluating pituitary gonadotropic function, and it has also been studied for fertility and hypothalamic disorders.
How it works: It activates pituitary GnRH receptors, triggering release of luteinizing hormone and follicle-stimulating hormone.
Pituitary function testing; fertility research; hypogonadism evaluation; hypothalamic amenorrhea
Research dose
100-500 mcg, Pulsatile: every 90–120 min (physiological); practical: 2×/day SubQ
Real-world (reported)
100–200 mcg SubQ 2×/day (morning + evening) during TRT. Some use 500 mcg 2×/day. Switch to pulsatile dosing device if available.
Administration
SubQ / IM / Intranasal
Timing
Morning + evening (practical pulsatile approximation)
Cycle length
Ongoing (TRT adjunct); or 4–8 wks (fertility/PCT)
Real-world figures are community-reported, not medical advice.
Common side effects: Headache; flushing; nausea; injection site reactions; abdominal discomfort
Community take: [ANECDOTAL – TRT community] Standard TRT adjunct to maintain testicular size and function. 'Keeps the boys working.' Preferred over HCG by some due to more physiological mechanism.
- Onset
- LH/FSH rise within hours; testicular volume 4–12 wks
- Half-life
- Approximately 4 minutes
- Storage
- Dry: Fridge 2–8°C; freeze long-term · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 2 mg vial = 1 mg/mL; 100 mcg = 10 IU
- Rare side effects
- Overstimulation syndrome (rare in males); anaphylaxis (rare); desensitization with continuous use
- Contraindications
- Pregnancy (if female partner using); hormone-sensitive cancers; continuous (non-pulsatile) use causes suppression; Pregnancy (potential effects on embryo/placental processes); Known hypersensitivity to gonadorelin or GnRH analogs; Hormone-sensitive reproductive tumors (theoretical concern); Lactation (GnRH-like bioactive peptides present in milk)Frequency distribution o
- Drug interactions
- GnRH analogs; sex hormones; prostate cancer medications
- Recommended bloodwork
- LH; FSH; testosterone; testicular volume; sperm count if fertility is goal
- Stacks well with
- HCG: alternative for LH/FSH stimulation on TRT. Kisspeptin-10: upstream stimulation.
- Secondary uses
- Prevent testicular atrophy on TRT; fertility preservation; hypogonadism treatment
- Legal status
- Withdrawn From Market
- Typical price
- $30–$70 / 2 mg vial
- Research evidence
- Approved - large human trials
- Indications
- Diagnostic testing of hypothalamic-pituitary-gonadal axis; Fertility treatment support; Hormone replacement therapy adjunct; Research into reproductive endocrinology
- Chemical data
- CAS 33515-09-2 · C55H75N17O13 · 1182.29 Da
- Amino acids
- 244 aa
Key risk: Rare severe hypersensitivity and anaphylactic reactions have been reported following administration.
Melanotan II
aka MT-II, MT-2
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone that non-selectively activates several melanocortin receptors, including MC1 and MC4. Through MC1 it darkens skin by stimulating melanin, and through MC4 it can influence sexual arousal and appetite. It is not approved for any human use and is sold only as an unregulated research chemical, and it is a different molecule from afamelanotide, which is Melanotan I.
How it works: It non-selectively activates melanocortin receptors, increasing skin melanin through MC1 and affecting sexual function through MC4.
Skin tanning; erectile function; appetite research; melanocortin studies
Research dose
250-1000 mcg, Daily (loading) then maintenance 2–3×/week
Real-world (reported)
Start low 250 mcg; build to 500–1000 mcg. Evening dose to sleep through nausea. UV exposure needed for tanning effect.
Administration
SubQ
Timing
Evening (nausea management)
Cycle length
Loading 1–2 wks; maintenance ongoing (with UV exposure for tanning)
Real-world figures are community-reported, not medical advice.
Common side effects: Facial flushing; nausea and vomiting; appetite loss; spontaneous erections; darkening of moles
Community take: [ANECDOTAL] Very popular for tanning. 'Barbie drug' in media. Community concern about mole changes — dermatology visits recommended. Libido effect strong.
- Onset
- Tanning 2–4 wks with UV; libido hours
- Half-life
- Not established in humans
- Storage
- Dry: Fridge 2–8°C; freeze long-term; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 10 mg vial = 5 mg/mL; 500 mcg dose = 10 IU
- Rare side effects
- Darkening/enlargement of moles (melanoma risk concern); melanoma case reports; prolonged erection; hypertension; hyperpigmentation of normal skin
- Contraindications
- Personal or family history of melanoma; active malignancy; pregnancy; cardiovascular disease; PT-141 preferred for pure sexual health (fewer pigmentation concerns); Uncontrolled hypertension or significant cardiovascular disease; History or risk of priapism; Pregnancy and lactation; Severe renal impairment
- Drug interactions
- Antihypertensives (additive BP effects); sexual function medications
- Recommended bloodwork
- Dermatology check (mole mapping) before and every 6 months; BP monitoring
- Stacks well with
- PT-141 (more selective; no tanning — choose one or the other based on goal).
- Secondary uses
- Appetite suppression; fat loss (secondary)
- Legal status
- Preclinical Research
- Typical price
- $25–$60 / 10 mg vial
- Research evidence
- Human trials - early or small
- Indications
- Melanogenesis and tanning research; Melanocortin receptor pharmacology studies; Sexual function research (led to development of PT-141); Appetite regulation and energy homeostasis studies
- Chemical data
- CAS 121062-08-6 · C50H69N15O9 · 1024.18 Da
- Amino acids
- 243 aa
Key risk: It has been associated with new and darkening melanocytic moles and reported cases of melanoma.
Alprostadil
aka Prostaglandin E1, PGE1, Caverject
Alprostadil is a synthetic form of prostaglandin E1 approved in the United States for erectile dysfunction and, in a separate intravenous formulation, for maintaining ductal patency in newborns with certain heart defects. It relaxes vascular and cavernosal smooth muscle, producing local vasodilation. Available formulations include intracavernosal injection and an intraurethral suppository.
How it works: It is a prostaglandin E1 agonist that raises intracellular cyclic AMP, relaxing smooth muscle and increasing local blood flow.
Erectile dysfunction; ED diagnostic use; neonatal ductus patency
Administration
IM
Timing
As needed before sexual activity (ED); continuous infusion (PDA)
Cycle length
Ongoing as needed for ED; until surgical correction for PDAStep-wise Titration
Common side effects: Penile pain; prolonged erection; penile fibrosis; injection site hematoma
- Half-life
- Approximately 10 minutes
- Storage
- Dry: Caverject lyophilized powder: store at or below 25 degrees C (77 degrees F). Reconstituted solution: use within 24 hours; do not refrigerate or freeze
- Reconstitution
- D5W or normal saline
- Contraindications
- Conditions predisposing to priapism: sickle cell disease or trait, multiple myel; Penile anatomical deformities: severe hypospadias, cavernosal fibrosis, Peyronie; Penile implants (for intracavernosal and intraurethral use); Urethral stricture, balanitis, or acute urethritis (for MUSE intraurethral use)
- Legal status
- Approved
- Research evidence
- Approved - large human trials
- Indications
- Erectile dysfunction treatment; Critical limb ischemia management; Patent ductus arteriosus maintenance in neonates; Peripheral arterial disease
- Chemical data
- CAS 745-65-3 · C20H34O5 · 354.48 Da
- Amino acids
- 51 aa
Key risk: Prolonged erection or priapism that can cause permanent penile tissue damage if not treated promptly.
Kisspeptin-10
aka KP-10, Metastin (45-54), Kisspeptin (112-121)
Kisspeptin-10 is a 10 amino acid peptide, the active C-terminal fragment of kisspeptin encoded by the KISS1 gene. It binds the KISS1 receptor on hypothalamic neurons and stimulates release of gonadotropin-releasing hormone, which in turn drives pituitary secretion of luteinizing hormone and follicle-stimulating hormone. It is studied mainly in reproductive endocrinology and fertility research.
How it works: It activates the KISS1 receptor on hypothalamic neurons, stimulating GnRH release and downstream luteinizing and follicle-stimulating hormone secretion.
GnRH stimulation; reproductive endocrinology; fertility research; puberty research
Research dose
0.3-3 mcg/kg, Pulsatile: every 90 min (physiological); practical: 1–2 ×/day SubQ
Real-world (reported)
50–100 mcg SubQ 1–2×/day. Very limited community protocols — follow clinical trial dosing.
Administration
SubQ / IV (clinical)
Timing
Morning and/or pre-sleep
Cycle length
Cyclical use; 2–4 wks on; break
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Very new in community. Used by biohackers for HPG axis optimization. 'Upstream of everything.' Limited gray-market experience.
- Onset
- LH pulse within hours; testosterone elevation 1–2 wks
- Half-life
- Approximately 4 minutes
- Storage
- Dry: Fridge 2–8°C; freeze long-term; very light sensitive · Reconstituted: Refrigerate; use within 14–21 days
- Reconstitution
- Add 1 mL BAC water to 1 mg vial = 1 mg/mL
- Rare side effects
- Desensitization with continuous non-pulsatile use (like GnRH analogs)
- Contraindications
- Hormone-sensitive cancers; pregnancy (causes GnRH overstimulation); continuous infusion (desensitizes); Sex hormone-sensitive cancers (breast; endometrial; ovarian; prostate) due to ki; Pregnancy (kisspeptin stimulates gonadotropin release which could disrupt early; Central precocious puberty (exogenous kisspeptin could further stimulate prematu; GnRH agonists and antagonists (pharm
- Drug interactions
- GnRH analogs; sex hormones; GPR54 modulators
- Recommended bloodwork
- LH (pre/post injection); testosterone; FSH; estradiol; LH pulsatility assessment
- Stacks well with
- Gonadorelin: complementary (different upstream levels of HPG axis). Both for TRT axis maintenance.
- Secondary uses
- Libido; mood; metabolic regulation; potential anti-tumor (emerging)
- Legal status
- Investigational
- Typical price
- $50–$120 / 1 mg vial
- Research evidence
- Human trials - early or small
- Indications
- Fertility and IVF research; Puberty onset studies; Reproductive endocrinology; Hypothalamic amenorrhea investigation
- Chemical data
- CAS 374675-21-5 · C257H383N69O74S3 · 5861.5 Da
- Amino acids
- 258 aa
LIB-01
aka Libiguin
LIB-01, also called Libiguin, is an investigational oral small molecule and a semisynthetic analogue of libiguin compounds from Neobeguea mahafalensis root bark. It is being developed for erectile dysfunction and acts as an indirect potentiator of central melanocortin-4 receptor signaling. A first-in-human trial reported improved erectile function that persisted for weeks after dosing despite rapid plasma clearance.
How it works: It is an indirect potentiator of central melanocortin-4 receptor signaling associated with sexual function.
Erectile dysfunction; sexual function research; premature ejaculation research
Administration
Oral
Timing
Oral tablet taken once daily for 3 consecutive days. Unique pharmacodynamic profile with onset within 7 days and sustained effect for 4-8 weeks after
Cycle length
3-day course; effects last 4-8 weeks
Common side effects: Nausea; vomiting; diarrhea; frequent bowel movements
- Half-life
- Not established
- Contraindications
- Not established -- LIB-01 is an investigational compound and formal contraindica; Women of childbearing potential should not use LIB-01 outside of clinical trials; No drug-drug interaction data have been published for LIB-01. Potential interact
- Legal status
- Investigational
- Research evidence
- Human trials - early or small
- Indications
- Erectile dysfunction treatment; Potential applications in premature ejaculation; Investigational use in metabolic diseases (preclinical)
- Chemical data
- C37H48O13 · 698.77 Da
- Amino acids
- 79 aa
Key risk: No boxed warning applies; a prolonged erection was reported in one early-trial participant and long-term safety is not established.
MVT-602
aka TAK-448, RVT-602
MVT-602 is a synthetic kisspeptin receptor agonist derived from kisspeptin-54 and engineered for greater stability and potency. In early clinical studies it triggered luteinizing hormone release and produced a more prolonged rise than native kisspeptin. It is investigational and has been studied for female reproductive conditions and as a possible trigger of egg maturation in fertility treatment, and it is not approved.
How it works: It is an agonist at the kisspeptin receptor on hypothalamic neurons, stimulating gonadotropin-releasing hormone and downstream LH and FSH.
Oocyte maturation trigger; hypothalamic amenorrhea research; polycystic ovary syndrome research; reproductive axis study
Administration
SC
Timing
Administered as a single injection to trigger oocyte maturation; LH surge peaks at 21-22 hours post-dose
Cycle length
Single administration
Common side effects: Not established
- Half-life
- 1.7 to 2 hours
- Contraindications
- Not established -- MVT-602 is investigational and formal contraindications have; Pregnancy (kisspeptin signaling modulates reproductive axis; effects on early pr; Known KISS1R-related conditions where additional kisspeptin signaling stimulatio; GnRH agonists and antagonists may interfere with MVT-602 mechanism since MVT-602
- Legal status
- Investigational
- Research evidence
- Human trials - early or small
- Indications
- Oocyte maturation trigger during IVF/medically assisted reproduction; Potential treatment for anovulatory disorders; Investigational use in hypogonadotropic hypogonadism
- Chemical data
- CAS 1234319-68-6 · C58H80N16O14 · 1225.36 Da
- Amino acids
- 251 aa
Example stacks
Libido - Beginner
PT-141 on-demand is the simplest and most validated starting point. FDA-approved for female sexual dysfunction.
- • Start at 0.5 mg and assess before moving to 1 mg
- • Allow the full 1-2 hr onset window
- • Inject in the abdomen or thigh
Libido - Intermediate
Kisspeptin-10 restores baseline hormonal signaling. PT-141 handles on-demand arousal. Addresses both the root hormonal cause and immediate response.
- • Space Kisspeptin evenly - e.g. Mon, Wed, Fri
- • Give Kisspeptin 4+ weeks to show hormonal effects
- • Test testosterone and estrogen before and after the cycle
Community outcome data
Collected from users researching this goal. Not a clinical database - for general reference only.
Share your experience
Your experience helps others research this goal. All submissions are anonymous.
Ready to actually use this research?
FREETwo tools that turn this research into something you can actually use - no signup needed.
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.